2020, Peru, Covid-19 EXCESS deaths: Ivermectin EFFECT

… In Peru, an opportunity to track the efficacy of IVM with a close consideration of confounding factors was provided

…  excess deaths as determined from Peruvian national health data were analyzed by state for ages ≥60

… compared with monthly summary data for excess deaths in Peru for the period 2020-2021 as published by the WHO in 2022

… Reductions in excess deaths over a period of 30 days after peak

… averaged 74% in the 10 states with the most intensive IVM use

… As determined across all 25 states correlated closely with the extent of IVM use (p<0.002)

… During four months of IVM use in 2020, before a new president of Peru restricted its use

… there was a 14-fold reduction in nationwide excess deaths

… then a 13-fold increase in the two months following the restriction of IVM use

… these trends in nationwide excess deaths align with WHO summary data for the same period in Peru

… The natural experiment … resulted in strong evidence for the drug’s effectiveness

… potential confounding factors, including effects of a social isolation mandate imposed in May 2020

… variations in the genetic makeup of the SARS-CoV-2 virus

… differences in seropositivity rates

… population densities across the 25 states

… were considered but did not appear to have significantly influenced these outcomes